Do analysts recommend AVCT or SCLP?

Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 41.88%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Avacta Group is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, AVCT or SCLP?

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 2,893.26 -£30.08M -£9.66 N/A Scancell £4.71M 30.84 -£6.75M -£0.55 N/A

Is AVCT or SCLP more profitable?

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Avacta Group -33,961.06% -2,929.47% -21.80% Scancell -116.98% 90.29% -45.28%

Do analysts rate SCLP or PRTC?

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 313.68%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is SCLP or PRTC more profitable?

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity. Company Net Margins Return on Equity Return on Assets Scancell -116.98% 90.29% -45.28% PureTech Health -2,355.32% -31.98% -13.39%

Scancell (SCLP) Competitors

GBX 14 +0.40 (+2.94%)

As of 03:19 AM Eastern

Compare

SCLP vs. SLN, AVCT, HZD, PRTC, and VRP

Should you buy Scancell stock or one of its competitors? MarketBeat compares Scancell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scancell include Silence Therapeutics (SLN), Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), and Verona Pharma plc (VRP.L) (VRP). These companies are all part of the "biotechnology" industry.

How does Scancell compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Scancell	Neutral

Silence Therapeutics has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Scancell	-116.98%	90.29%	-45.28%

Silence Therapeutics has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Scancell	£4.71M	30.84	-£6.75M	-£0.55	N/A

1.5% of Scancell shares are held by institutional investors. 15.5% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Silence Therapeutics and Scancell tied by winning 4 of the 8 factors compared between the two stocks.

How does Scancell compare to Avacta Group?

Avacta Group (LON:AVCT) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

3.1% of Avacta Group shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by company insiders. Comparatively, 15.5% of Scancell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 41.88%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Avacta Group is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,893.26	-£30.08M	-£9.66	N/A
Scancell	£4.71M	30.84	-£6.75M	-£0.55	N/A

In the previous week, Avacta Group had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Scancell. Avacta Group's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
Scancell	Neutral

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Scancell	-116.98%	90.29%	-45.28%

Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Scancell has a beta of 0.736, indicating that its stock price is 26% less volatile than the broader market.

Summary

Avacta Group beats Scancell on 10 of the 15 factors compared between the two stocks.

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Scancell (LON:SCLP) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

1.5% of Scancell shares are owned by institutional investors. 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	30.84	-£6.75M	-£0.55	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

In the previous week, Scancell's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Summary

Scancell beats Horizon Discovery Group plc (HZD.L) on 5 of the 8 factors compared between the two stocks.

How does Scancell compare to PureTech Health?

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

In the previous week, PureTech Health had 6 more articles in the media than Scancell. MarketBeat recorded 6 mentions for PureTech Health and 0 mentions for Scancell. PureTech Health's average media sentiment score of 1.63 beat Scancell's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Scancell	Neutral
PureTech Health	Very Positive

1.5% of Scancell shares are held by institutional investors. Comparatively, 33.5% of PureTech Health shares are held by institutional investors. 15.5% of Scancell shares are held by company insiders. Comparatively, 13.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Scancell has higher revenue and earnings than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	30.84	-£6.75M	-£0.55	N/A
PureTech Health	£4.66M	64.16	-£91.86M	-£46.00	N/A

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Scancell has a beta of 0.736, indicating that its share price is 26% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.793, indicating that its share price is 21% less volatile than the broader market.

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 313.68%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

PureTech Health beats Scancell on 10 of the 16 factors compared between the two stocks.

How does Scancell compare to Verona Pharma plc (VRP.L)?

Scancell (LON:SCLP) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Verona Pharma plc (VRP.L) has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	30.84	-£6.75M	-£0.55	N/A
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

In the previous week, Scancell's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
Verona Pharma plc (VRP.L)	Neutral

1.5% of Scancell shares are owned by institutional investors. 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Verona Pharma plc (VRP.L) has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

Summary

Scancell beats Verona Pharma plc (VRP.L) on 5 of the 8 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLP vs. The Competition

Export

Metric	Scancell	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£145.29M	£508.33M	£7.05B	£2.85B
Dividend Yield	N/A	3.90%	2.68%	6.16%
P/E Ratio	-25.45	3.14	27.11	368.21
Price / Sales	30.84	6,436.17	587.92	84,612.73
Price / Cash	7.86	13.13	29.22	27.87
Price / Book	-35.92	85.93	10.75	7.49
Net Income	-£6.75M	-£96.07M	£3.58B	£5.89B
7 Day Performance	-5.72%	-0.93%	-2.06%	-0.19%
1 Month Performance	-28.20%	2.45%	3.32%	-0.99%
1 Year Performance	43.37%	60.19%	26.36%	61.68%

Scancell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLP Scancell	N/A	GBX 14 +2.9%	N/A	+32.2%	£145.29M	£4.71M	N/A	51
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	1.6339 of 5 stars	GBX 72.37 -0.2%	GBX 99 +36.8%	+114.8%	£329.36M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.7687 of 5 stars	GBX 117.20 -5.6%	GBX 508 +333.4%	-5.4%	£285.29M	£4.66M	N/A	300	Positive News Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SCLP) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scancell (SCLP) Competitors

SCLP vs. SLN, AVCT, HZD, PRTC, and VRP

How does Scancell compare to Silence Therapeutics?

Summary

How does Scancell compare to Avacta Group?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Scancell compare to PureTech Health?

Summary

How does Scancell compare to Verona Pharma plc (VRP.L)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scancell (SCLP) Competitors

SCLP vs. SLN, AVCT, HZD, PRTC, and VRP

How does Scancell compare to Silence Therapeutics?

Does the media refer more to SLN or SCLP?

Is SLN or SCLP more profitable?

Which has higher earnings and valuation, SLN or SCLP?

Do insiders & institutionals believe in SLN or SCLP?

Summary

How does Scancell compare to Avacta Group?

Do insiders & institutionals believe in AVCT or SCLP?

Do analysts recommend AVCT or SCLP?

Which has better earnings & valuation, AVCT or SCLP?

Does the media prefer AVCT or SCLP?

Is AVCT or SCLP more profitable?

Which has more volatility & risk, AVCT or SCLP?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Do institutionals and insiders hold more shares of SCLP or HZD?

Is SCLP or HZD more profitable?

Which has higher earnings & valuation, SCLP or HZD?

Does the media favor SCLP or HZD?

Summary

How does Scancell compare to PureTech Health?

Does the media refer more to SCLP or PRTC?

Do institutionals and insiders believe in SCLP or PRTC?

Which has better valuation & earnings, SCLP or PRTC?

Is SCLP or PRTC more profitable?

Which has more volatility and risk, SCLP or PRTC?

Do analysts rate SCLP or PRTC?

Summary

How does Scancell compare to Verona Pharma plc (VRP.L)?

Which has better earnings & valuation, SCLP or VRP?

Does the media prefer SCLP or VRP?

Do insiders and institutionals have more ownership in SCLP or VRP?

Is SCLP or VRP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools